

North America In-vitro Diagnostics Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 150 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

North America In-vitro Diagnostics Market Report and Forecast 2024-2032

The North America in-vitro diagnostics market is expected to grow at a CAGR of 3% during the period 2024-2032 driven by the increasing prevalence of chronic diseases across the region.

North America In-vitro Diagnostics Market Analysis

The North American in-vitro diagnostics (IVD) market is a significant segment of the global healthcare industry, encompassing a wide array of diagnostic tests and tools used to detect diseases, conditions, and infections. These diagnostics are crucial in the medical field, aiding in disease prevention, diagnosis, and treatment. The market includes various tests performed on blood, tissues, and other samples collected from the human body. The increasing prevalence of chronic diseases, advancements in diagnostic technologies, and rising awareness about early disease detection drive the market growth in this region.

Market Drivers

- **Technological Advancements:** The continuous innovation and development of new diagnostic technologies, such as next-generation sequencing (NGS), point-of-care testing, and molecular diagnostics, are significantly boosting the market. These advancements provide more accurate, efficient, and faster diagnostic results, improving patient outcomes.
- **Increasing Prevalence of Chronic Diseases:** The rising incidence of chronic diseases such as diabetes, cancer, and cardiovascular diseases necessitates early and accurate diagnostics. IVD plays a crucial role in early detection and monitoring of these conditions, thus driving the market growth.
- **Growing Geriatric Population:** An ageing population in North America is more susceptible to various diseases, thereby increasing the demand for diagnostic tests. The need for regular health check-ups and disease monitoring among the elderly fuels the IVD market.
- **Government Initiatives and Funding:** Supportive government policies and increased funding for healthcare research and diagnostics infrastructure contribute to market expansion. Initiatives aimed at improving healthcare access and quality further enhance market growth.

Challenges

- **Regulatory Hurdles:** The stringent regulatory requirements for the approval of new diagnostic tests can delay market entry and increase costs for manufacturers. Compliance with diverse regulatory standards across North America poses a significant

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

challenge.

- High Costs: The development and implementation of advanced diagnostic technologies involve substantial costs, making them expensive for end-users. High costs can limit the adoption of these tests, particularly in low-income populations.
- Data Privacy Concerns: The increasing use of digital technologies in diagnostics raises concerns about data privacy and security. Ensuring the confidentiality and protection of patient data is a critical challenge for market players.
- Limited Reimbursement: Inadequate reimbursement policies for certain diagnostic tests can hinder market growth. Limited coverage and low reimbursement rates can discourage patients from opting for advanced diagnostic procedures.

Future Opportunities

- Personalised Medicine: The growing trend towards personalised medicine, which tailors treatment plans based on individual genetic profiles, offers significant opportunities for the IVD market. Advances in genetic and molecular diagnostics will play a key role in this area.
- Point-of-Care Testing (POCT): The increasing demand for POCT, which allows for rapid and convenient diagnostic testing at or near the point of care, presents a major growth opportunity. POCT is particularly valuable in remote and underserved areas, enhancing healthcare accessibility.
- Integration of Artificial Intelligence (AI): The integration of AI and machine learning in diagnostics can revolutionise the IVD market. AI-powered tools can enhance diagnostic accuracy, predict disease outbreaks, and provide personalised treatment recommendations.
- Expansion in Emerging Markets: While North America remains a dominant player, expanding into emerging markets within the region, such as Mexico, offers growth potential. These markets have a growing need for advanced diagnostics due to improving healthcare infrastructure and rising healthcare awareness.
- Collaborations and Partnerships: Strategic collaborations between diagnostic companies, research institutions, and healthcare providers can foster innovation and accelerate the development and adoption of new diagnostic tests. Partnerships can also facilitate market entry and expansion.

North America In-vitro Diagnostics Market Trends

The North American in-vitro diagnostics (IVD) market is experiencing significant growth, driven by advancements in technology and a rising emphasis on early disease detection. This sector is witnessing several key trends that are shaping its future trajectory.

- Adoption of Next-Generation Sequencing (NGS): NGS is revolutionising the IVD market by providing detailed genetic information that aids in personalised medicine. This technology is increasingly being used for diagnosing complex genetic disorders, cancer, and infectious diseases, offering precise and comprehensive insights.
- Rise of Point-of-Care Testing (POCT): There is a growing demand for POCT due to its convenience, speed, and ability to deliver immediate results. This trend is particularly evident in rural and remote areas where access to traditional laboratory facilities is limited, improving patient care and health outcomes.
- Integration of Artificial Intelligence (AI) and Machine Learning: AI and machine learning are being integrated into diagnostic tools to enhance accuracy and efficiency. These technologies enable predictive analytics, automate complex data analysis, and support personalised treatment plans, leading to better patient management.
- Expansion of Home-Based Testing: The COVID-19 pandemic has accelerated the adoption of home-based diagnostic testing. Consumers are increasingly opting for at-home test kits for various conditions, including chronic disease monitoring and infectious disease detection, driven by convenience and safety concerns.
- Focus on Biomarker Discovery and Validation: There is a growing emphasis on discovering and validating new biomarkers for various diseases. This trend is crucial for the development of more specific and sensitive diagnostic tests, improving early detection and treatment outcomes.

North America In-vitro Diagnostics Market Segmentation

Market Breakup by Product Type

- Reagents and Kits
- Instruments
- Software and Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The North American in-vitro diagnostics (IVD) market is segmented into reagents and kits, instruments, and software and services. Reagents and kits dominate due to their extensive use in diagnostic tests, driven by the rising prevalence of chronic diseases. Instruments are witnessing growth due to technological advancements and the increasing adoption of automated systems. Software and services are expanding rapidly, fuelled by the integration of AI and data analytics, enhancing diagnostic accuracy and efficiency. These segments collectively propel market growth, with a forecasted increase due to advancements in technology, rising healthcare awareness, and a growing emphasis on early disease detection.

Market Breakup by Technology

- Immunoassay/ Immunochemistry
- Clinical Chemistry
- Molecular Diagnostics
- Haematology
- Microbiology
- Blood Glucose Self-Monitoring
- Coagulation and Haemostasis
- Urinalysis
- Others

The North American in-vitro diagnostics (IVD) market is segmented by technology into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, haematology, microbiology, blood glucose self-monitoring, coagulation and haemostasis, urinalysis, and others. Immunoassays and immunochemistry lead due to their widespread application in disease detection and monitoring. Molecular diagnostics is growing rapidly, driven by advancements in genetic testing and personalised medicine. Clinical chemistry and haematology benefit from routine use in hospitals and laboratories. Blood glucose self-monitoring sees significant demand due to rising diabetes prevalence. The growth in these technologies is poised to drive market expansion, emphasising technological innovation and improved healthcare outcomes.

Market Breakup by Therapeutic Area

- Infectious Diseases
- Diabetes
- Cardiology
- Oncology
- Autoimmune Diseases
- Nephrology
- Others

The North American in-vitro diagnostics (IVD) market is segmented by therapeutic area into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, and others. Infectious diseases dominate due to the ongoing need for rapid and accurate diagnostic tests, especially highlighted by the COVID-19 pandemic. Diabetes diagnostics see sustained demand driven by the high prevalence of the condition. Cardiology and oncology are experiencing growth due to advancements in biomarkers and personalised medicine approaches. Autoimmune diseases and nephrology segments are expanding as awareness and early diagnosis improve. These therapeutic areas collectively drive market growth, emphasising the importance of early and precise disease detection.

Market Breakup by End User

- Hospitals
- Laboratories

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Homecare
- Others

The North American in-vitro diagnostics (IVD) market is segmented by end user into hospitals, laboratories, homecare, and others. Hospitals dominate due to the high volume of diagnostic tests performed in these settings, driven by the need for accurate and timely disease diagnosis. Laboratories also hold a significant share, benefiting from advancements in automation and high-throughput technologies. Homecare diagnostics are rapidly growing, spurred by the increasing preference for convenient and cost-effective home-based testing, particularly for chronic disease management. These end-user segments collectively propel market growth, with innovations in technology and a focus on patient-centric care driving future expansion.

Market Breakup by Country

- United States
- Canada

The North American in-vitro diagnostics (IVD) market is segmented by country into the United States and Canada. The United States leads the market due to its advanced healthcare infrastructure, significant investments in research and development, and the presence of major IVD companies. The high prevalence of chronic diseases and the adoption of advanced diagnostic technologies further drive market growth. Canada, while smaller, is experiencing steady growth fueled by increasing healthcare spending, advancements in diagnostic technologies, and a growing focus on preventive healthcare. Both countries contribute to the overall market expansion, with innovations and healthcare improvements driving future growth.

North America In-vitro Diagnostics Market Competitive Landscape

The competitive landscape of the North American in-vitro diagnostics (IVD) market is robust, with key players including F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, bioMerieux SA, Abbott Laboratories, Quidel Corporation, OraSure Technologies, Inc., Thermo Fisher Scientific Inc, Hologic, Inc., and Cepheid Inc (Danaher Corp.). These companies engage in various market activities such as mergers and acquisitions to expand their market presence and capabilities, extensive research initiatives to innovate and improve diagnostic solutions, and frequent product introductions to meet evolving healthcare needs. Strategic partnerships and collaborations are also common, facilitating advancements in technology and expanding the reach of diagnostic products. This dynamic environment fosters continuous growth and innovation within the IVD market, ensuring the development of cutting-edge diagnostic tools and enhanced healthcare outcomes.

Key Questions Answered in the Report

- ?□What is the current and future performance of the North America In-vitro Diagnostics market?
- ?□What are the main challenges facing the North America In-vitro Diagnostics market?
- ?□What are the key drivers of the North America In-vitro Diagnostics market?
- ?□What emerging trends are shaping the future of the North America In-vitro Diagnostics market?
- ?□How is the trend towards personalised medicine influencing the development of companion diagnostics?
- ?□Why do reagents and kits dominate the IVD market, and how are instruments evolving?
- ?□How are molecular diagnostics, clinical chemistry, and haematology evolving in the IVD market?
- ?□What factors are driving the sustained demand for diabetes diagnostics?
- ?□Why do hospitals dominate the IVD market in terms of diagnostic test volumes?

Key Benefits for Stakeholders

- ?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the North America In-vitro Diagnostics market from 2017-2032.
- ?□The research report provides the latest information on the market drivers, challenges, and opportunities in the North America In-vitro Diagnostics market.
- ?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the North America In-vitro Diagnostics industry and its attractiveness.

The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 In-vitro Diagnostics Market Overview
 - 3.1 Global In-vitro Diagnostics Market
 - 3.1.1 Global In-vitro Diagnostics Market Historical Value (2017-2023)
 - 3.1.2 Global In-vitro Diagnostics Market Forecast Value (2024-2032)
 - 3.2 North America In-vitro Diagnostics Market
 - 3.2.1 North America In-vitro Diagnostics Market Historical Value (2017-2023)
 - 3.2.2 North America In-vitro Diagnostics Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 North America In-vitro Diagnostics Market Landscape*
 - 5.1 North America In-vitro Diagnostics: Developers Landscape
 - 5.1.1 Analysis by Year of Establishment
 - 5.1.2 Analysis by Company Size
 - 5.1.3 Analysis by Region
 - 5.2 North America In-vitro Diagnostics: Product Landscape
 - 5.2.1 Analysis by Product Type
 - 5.2.2 Analysis by Technology
 - 5.2.3 Analysis by Therapeutic Area
 - 5.2.4 Analysis by End User
- 6 North America In-vitro Diagnostics Market Dynamics
 - 6.1 Market Drivers and Constraints
 - 6.2 SWOT Analysis
 - 6.2.1 Strengths
 - 6.2.2 Weaknesses
 - 6.2.3 Opportunities
 - 6.2.4 Threats
 - 6.3 PESTEL Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants
 - 6.4.4 Threat of Substitutes
 - 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 North America In-vitro Diagnostics Market: Trade Data Analysis (HS Code- 38220090)
 - 7.1 Major Exporting Countries
 - 7.1.1 By Value
 - 7.1.2 By Volume
 - 7.2 Major Importing Countries
 - 7.2.1 By Value
 - 7.2.2 By Volume
- 8 North America In-vitro Diagnostics Market Segmentation (2017-2032)
 - 8.1 North America In-vitro Diagnostics Market (2017-2032) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Reagents and Kits
 - 8.1.3 Instruments
 - 8.1.4 Software and Services
 - 8.2 North America In-vitro Diagnostics Market (2017-2032) by Technology
 - 8.2.1 Market Overview
 - 8.2.2 Immunoassay/ Immunochemistry
 - 8.2.3 Clinical Chemistry
 - 8.2.4 Molecular Diagnostics
 - 8.2.5 Haematology
 - 8.2.6 Microbiology
 - 8.2.7 Blood Glucose Self-Monitoring
 - 8.2.8 Coagulation and Haemostasis
 - 8.2.9 Urinalysis
 - 8.2.10 Others
 - 8.3 North America In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
 - 8.3.1 Market Overview
 - 8.3.2 Infectious Diseases
 - 8.3.3 Diabetes
 - 8.3.4 Cardiology
 - 8.3.5 Oncology
 - 8.3.6 Autoimmune Diseases

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.7 Nephrology
- 8.3.8 Others
- 8.4 North America In-vitro Diagnostics Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Hospitals
 - 8.4.3 Laboratories
 - 8.4.4 Homecare
 - 8.4.5 Others
- 8.5 North America In-vitro Diagnostics Market (2017-2032) by Country
 - 8.5.1 Market Overview
 - 8.5.2 United States
 - 8.5.3 Canada
- 9 United States In-vitro Diagnostics Market Segmentation (2017-2032)
 - 9.1 United States In-vitro Diagnostics Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Reagents and Kits
 - 9.1.3 Instruments
 - 9.1.4 Software and Services
 - 9.2 United States In-vitro Diagnostics Market (2017-2032) by Technology
 - 9.2.1 Market Overview
 - 9.2.2 Immunoassay/ Immunochemistry
 - 9.2.3 Clinical Chemistry
 - 9.2.4 Molecular Diagnostics
 - 9.2.5 Haematology
 - 9.2.6 Microbiology
 - 9.2.7 Blood Glucose Self-Monitoring
 - 9.2.8 Coagulation and Haemostasis
 - 9.2.9 Urinalysis
 - 9.2.10 Others
 - 9.3 United States In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
 - 9.3.1 Market Overview
 - 9.3.2 Infectious Diseases
 - 9.3.3 Diabetes
 - 9.3.4 Cardiology
 - 9.3.5 Oncology
 - 9.3.6 Autoimmune Diseases
 - 9.3.7 Nephrology
 - 9.3.8 Others
 - 9.4 United States In-vitro Diagnostics Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Hospitals
 - 9.4.3 Laboratories
 - 9.4.4 Homecare
 - 9.4.5 Others
- 10 Canada In-vitro Diagnostics Market Segmentation (2017-2032)
 - 10.1 Canada In-vitro Diagnostics Market (2017-2032) by Product Type
 - 10.1.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.2 Reagents and Kits
- 10.1.3 Instruments
- 10.1.4 Software and Services
- 10.2 Canada In-vitro Diagnostics Market (2017-2032) by Technology
 - 10.2.1 Market Overview
 - 10.2.2 Immunoassay/ Immunochemistry
 - 10.2.3 Clinical Chemistry
 - 10.2.4 Molecular Diagnostics
 - 10.2.5 Haematology
 - 10.2.6 Microbiology
 - 10.2.7 Blood Glucose Self-Monitoring
 - 10.2.8 Coagulation and Haemostasis
 - 10.2.9 Urinalysis
 - 10.2.10 Others
- 10.3 Canada In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
 - 10.3.1 Market Overview
 - 10.3.2 Infectious Diseases
 - 10.3.3 Diabetes
 - 10.3.4 Cardiology
 - 10.3.5 Oncology
 - 10.3.6 Autoimmune Diseases
 - 10.3.7 Nephrology
 - 10.3.8 Others
- 10.4 Canada In-vitro Diagnostics Market (2017-2032) by End User
 - 10.4.1 Market Overview
 - 10.4.2 Hospitals
 - 10.4.3 Laboratories
 - 10.4.4 Homecare
 - 10.4.5 Others
- 11 Regulatory Framework
 - 11.1 Regulatory Overview
 - 11.2 FDA
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication Year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Strategic Initiative
 - 13.1 Analysis by Partnership Instances
 - 13.2 Analysis by Type of Partnership
 - 13.3 Analysis by Leading Players
 - 13.4 Analysis by Geography
- 14 Supplier Landscape
 - 14.1 Market Share Analysis, By Region (Top 5 Companies)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.1 Market Share Analysis: North America
- 14.2 F. Hoffmann-La Roche Ltd
 - 14.2.1 Financial Analysis
 - 14.2.2 Product Portfolio
 - 14.2.3 Demographic Reach and Achievements
 - 14.2.4 Mergers and Acquisitions
 - 14.2.5 Certifications
- 14.3 Becton, Dickinson and Company
 - 14.3.1 Financial Analysis
 - 14.3.2 Product Portfolio
 - 14.3.3 Demographic Reach and Achievements
 - 14.3.4 Mergers and Acquisitions
 - 14.3.5 Certifications
- 14.4 Bio-Rad Laboratories, Inc .
 - 14.4.1 Financial Analysis
 - 14.4.2 Product Portfolio
 - 14.4.3 Demographic Reach and Achievements
 - 14.4.4 Mergers and Acquisitions
 - 14.4.5 Certifications
- 14.5 Siemens Healthineers AG
 - 14.5.1 Financial Analysis
 - 14.5.2 Product Portfolio
 - 14.5.3 Demographic Reach and Achievements
 - 14.5.4 Mergers and Acquisitions
 - 14.5.5 Certifications
- 14.6 bioMérieux SA
 - 14.6.1 Financial Analysis
 - 14.6.2 Product Portfolio
 - 14.6.3 Demographic Reach and Achievements
 - 14.6.4 Mergers and Acquisitions
 - 14.6.5 Certifications
- 14.7 Abbott Laboratories
 - 14.7.1 Financial Analysis
 - 14.7.2 Product Portfolio
 - 14.7.3 Demographic Reach and Achievements
 - 14.7.4 Mergers and Acquisitions
 - 14.7.5 Certifications
- 14.8 Quidel Corporation
 - 14.8.1 Financial Analysis
 - 14.8.2 Product Portfolio
 - 14.8.3 Demographic Reach and Achievements
 - 14.8.4 Mergers and Acquisitions
 - 14.8.5 Certifications
- 14.9 OraSure Technologies, Inc .
 - 14.9.1 Financial Analysis
 - 14.9.2 Product Portfolio
 - 14.9.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.9.4 Mergers and Acquisitions
- 14.9.5 Certifications
- 14.10 Thermo Fisher Scientific Inc
 - 14.10.1 Financial Analysis
 - 14.10.2 Product Portfolio
 - 14.10.3 Demographic Reach and Achievements
 - 14.10.4 Mergers and Acquisitions
 - 14.10.5 Certifications
- 14.11 Hologic, Inc .
 - 14.11.1 Financial Analysis
 - 14.11.2 Product Portfolio
 - 14.11.3 Demographic Reach and Achievements
 - 14.11.4 Mergers and Acquisitions
 - 14.11.5 Certifications
- 14.12 Cepheid Inc (Danaher Corp .)
 - 14.12.1 Financial Analysis
 - 14.12.2 Product Portfolio
 - 14.12.3 Demographic Reach and Achievements
 - 14.12.4 Mergers and Acquisitions
 - 14.12.5 Certifications
- 15 North America In-vitro Diagnostics Market - Distribution Model (Additional Insight)
 - 15.1 Overview
 - 15.2 Potential Distributors
 - 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America In-vitro Diagnostics Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 150 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com